Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.

Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.

Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia. This febrile period is typically followed by the appearance of a rash that evolves sequentially: initial macules (flat, erythematous lesions) progress to papules, then to fluid-filled vesicles, and later to pustules. The pustular stage is followed by crusting into scabs, which eventually fall off, often leaving deep, pitted pockmarks—especially on facial skin. The synchronous progression of lesions through these stages is a hallmark of smallpox.

Viral Replication and Pathogenesis

• Cytoplasmic replication: Variola major carries genes encoding DNA-dependent RNA polymerase and other essential enzymes, enabling replication entirely within the host cell cytoplasm and evading some nuclear antiviral defenses.
• Macrophage transport: Virus uptake by macrophages facilitates dissemination and may contribute to immune system dysregulation.
• Viremia and rash formation: The onset of viremia corresponds temporally with the rash appearance, reflecting systemic dissemination and cutaneous involvement.

Diagnosis: Smallpox diagnosis relies primarily on clinical presentation, particularly the synchronous progression of skin lesions and history of exposure. Laboratory confirmation is achieved through polymerase chain reaction (PCR) testing of lesion fluid, electron microscopy, or viral culture in biosafety level 4 (BSL-4) facilities. Serological assays and immunohistochemistry can provide supportive evidence.

Treatment: No specific antiviral treatment is universally approved for smallpox. However, antiviral agents such as tecovirimat (ST-246), approved for use under specific emergency protocols, have shown efficacy in inhibiting viral envelope formation. Cidofovir and brincidofovir have also demonstrated in vitro activity against poxviruses. Supportive care, including hydration, fever management, and secondary infection control, remains critical.

Prevention: Preventive strategies historically relied on the vaccinia virus-based smallpox vaccine, which induces cross-protective immunity. The vaccine, which uses a live, attenuated virus, is highly effective if administered before or within a few days of exposure. Routine vaccination ceased after eradication in 1980 but remains part of biodefense stockpiles in several countries. Ring vaccination and isolation remain critical control measures in outbreak scenarios.